ReviewFrontiers in genetics2014
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial.
Review in Frontiers in genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 95 citations in OpenAlex.
- Trial
- From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer.BMC cancer · 2015Trial
- Impact of molecular tumor board on clinical outcomes in patients with refractory solid tumors: a real-world study.The oncologist · 2026Article
- Integrative bioinformatics and deep learning to identify common genetic pathways in Crohn's disease and ischemic cardiomyopathy.Journal, genetic engineering & biotechnology · 2025Article
- Actionability classification of variants of unknown significance correlates with functional effect.NPJ precision oncology · 2023Article
- CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis.Scientific reports · 2023Article
- Characterizing Alcohol Expectancies in the ABCD Study: Associations with Sociodemographic Factors, the Immediate Social Environment, and Genetic Propensities.Behavior genetics · 2023Article
- Identification of Hub Diagnostic Biomarkers and Candidate Therapeutic Drugs in Heart Failure.International journal of general medicine · 2022Article
- A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.NPJ precision oncology · 2021Article
- Enhancing Knowledge Graph Extraction and Validation From Scholarly Publications Using Bibliographic Metadata.Frontiers in research metrics and analytics · 2021Article
- Identification of Key Biomarkers and Immune Infiltration in Sciatic Nerve of Diabetic Neuropathy BKS-db/db Mice by Bioinformatics Analysis.Frontiers in pharmacology · 2021Article
- Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.BMC cancer · 2020Article
- Construction of a 14-lncRNA risk score system predicting survival of children with acute myelocytic leukemia.Experimental and therapeutic medicine · 2020Article
- Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Molecular Profiling of Advanced Malignancies: A Community Oncology Network Experience and Review of Literature.Frontiers in medicine · 2020Article
- Metabolomics technology and bioinformatics for precision medicine.Briefings in bioinformatics · 2019Review
- SFTA1P, LINC00968, GATA6-AS1, TBX5-AS1, and FEZF1-AS1 are crucial long non-coding RNAs associated with the prognosis of lung squamous cell carcinoma.Oncology letters · 2019Article
- HTR1D, TIMP1, SERPINE1, MMP3 and CNR2 affect the survival of patients with colon adenocarcinoma.Oncology letters · 2019Article
- Mining conditions specific hub genes from RNA-Seq gene-expression data via biclustering and their application to drug discovery.IET systems biology · 2019Article
- A 9‑lncRNA risk score system for predicting the prognosis of patients with hepatitis B virus‑positive hepatocellular carcinoma.Molecular medicine reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine (PM) requires the delivery of individually adapted medical care based on the genetic characteristics of each patient and his/her tumor. The last decade witnessed the development of high-throughput technologies such as microarrays and next-generation sequencing which paved the way to PM in the field of oncology. While the cost of these technologies decreases, we are facing an exponential increase in the amount of data produced. Our ability to use this information in daily practice relies strongly on the availability of an efficient bioinformatics system that assists in the translation of knowledge from the bench towards molecular targeting and diagnosis. Clinical trials and routine diagnoses constitute different approaches, both requiring a strong bioinformatics environment capable of (i) warranting the integration and the traceability of data, (ii) ensuring the correct processing and analyses of genomic data, and (iii) applying well-defined and reproducible procedures for workflow management and decision-making. To address the issues, a seamless information system was developed at Institut Curie which facilitates the data integration and tracks in real-time the processing of individual samples. Moreover, computational pipelines were developed to identify reliably genomic alterations and mutations from the molecular profiles of each patient. After a rigorous quality control, a meaningful report is delivered to the clinicians and biologists for the therapeutic decision. The complete bioinformatics environment and the key points of its implementation are presented in the context of the SHIVA clinical trial, a multicentric randomized phase II trial comparing targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer. The numerous challenges faced in practice during the setting up and the conduct of this trial are discussed as an illustration of PM application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.